It’s been quite a while since we last touched upon Viaderma Inc (OTCMKTS:VDRM), and this week shares have been on the rise for the first time in a few months, so we wanted to check in on the company’s status. We’re always looking for a good bottom play and the stock has made some decent headway coming off its recently registered new annual low.
ViaDerma’s products use a transdermal delivery (absorption through the skin) method that allows for application of active ingredients in a topical form. This patent-pending dual carrier transdermal technology may be applied in products within the medical and cosmetic markets- a patent application using the combination of CBD and THC with the delivery system was filed in 2017. The use of CBD is for the reduction of inflammation and for the treatment of several diseases, such as, nicotine addiction, fibromyalgia, Cohn’s disease, schizophrenia, migraine headaches, pain management for cancer and Multiple Sclerosis.
Viaderma Inc (OTCMKTS:VDRM) has just announced that it has appointed Galaxy Solutions, Inc. as its sales representative for its first aid topical antibiotic which will be sold under the brand name Vitastem in select markets of Asia Pacific, starting in Japan. The agreement includes sales and marketing responsibilities of the Vitastem brand and possible other brands that will be developed for specific market segments. Galaxy Solutions, Inc. will work to sell directly to larger customers and to distributors and will be the primary provider of service and support in the covered markets.
“With Galaxy Solutions as our sales representative, we will immediately have access to the professional segment of our target markets,” said Dr. Chris Otiko, CEO of Viaderma, Inc. “Our goal is to continuously increase our revenues and improve our customers’ experience in every aspect. Expanding our network of sales and support personnel and being in close proximity to where our customers are is a key initiative towards achieving that. With competitive pricing for retail sales through doctor’s offices in Japan, the Company is conservatively estimating 2018 sales in Japan alone at approximately $12 million US dollars.”
“Over the last 7 years Galaxy Solutions has established itself as a premier supplier of epidermal healing solutions, anti-aging solutions and beautification solutions. The relationship with Galaxy Solutions, Inc. will allow us to introduce our products to several markets, initially in Japan and then throughout Asia Pacific, immediately,” said Otiko.
“Product testing has already begun and we are expecting to place an initial order in the next 30-45 days. I expect sales to be at around 10,000 units per month in the first 4-6 months and we hope to double that to 20,000 units per month in 2018 in Japan alone. The current testing is being done on sores resulting form side effects of cancer treatments and this will be our initial market, next we expect to introduce a product for acne,” said Don Heath, President and CEO of Galaxy Solutions, Inc. (Source: Market Wired)
It will be interesting to see what kind of market penetration the company can actually achieve in places like Japan and the Philippines, especially with the help of a regionally established marketing firm. Additionally whether the figures will meet or exceed the projections given. Stay locked to Street Register for updates, and we’ll deliver important developments on VDRM as they unfold. In the meantime, if you’ve yet to sign up for our 100% free newsletter, do so now! Just enter your active email address into the box below and submit!
Disclosure: No one at Street Register has been compensated in any way for the publishing of this article, nor do we hold any position in VDRM stock, short or long.